Tango Therapeutics, Inc. (NASDAQ:TNGX) Insider Adam Crystal Sells 7,432 Shares

Tango Therapeutics, Inc. (NASDAQ:TNGX) insider Adam Crystal sold 7,432 shares of Tango Therapeutics stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $2.99, for a total value of $22,221.68. Following the transaction, the insider now directly owns 165,061 shares of the company’s stock, valued at $493,532.39. This trade represents a 4.31 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Tango Therapeutics Stock Down 2.7 %

Shares of TNGX opened at $3.26 on Friday. The business’s 50 day moving average is $3.14 and its two-hundred day moving average is $6.12. Tango Therapeutics, Inc. has a 52-week low of $2.59 and a 52-week high of $12.89.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on TNGX. Guggenheim cut their target price on shares of Tango Therapeutics from $18.00 to $8.00 and set a “buy” rating for the company in a research note on Thursday, November 7th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Tango Therapeutics in a report on Thursday, December 5th. HC Wainwright reiterated a “buy” rating and set a $13.00 target price on shares of Tango Therapeutics in a report on Friday, November 8th. Finally, B. Riley decreased their target price on Tango Therapeutics from $16.00 to $8.00 and set a “buy” rating for the company in a report on Monday, November 11th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, Tango Therapeutics presently has an average rating of “Buy” and an average price target of $13.14.

Institutional Investors Weigh In On Tango Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. The Manufacturers Life Insurance Company raised its position in shares of Tango Therapeutics by 8.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 29,511 shares of the company’s stock valued at $253,000 after acquiring an additional 2,218 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of Tango Therapeutics by 64.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 20,607 shares of the company’s stock valued at $159,000 after acquiring an additional 8,055 shares in the last quarter. Quest Partners LLC raised its position in shares of Tango Therapeutics by 1,448.4% during the 3rd quarter. Quest Partners LLC now owns 10,885 shares of the company’s stock valued at $84,000 after acquiring an additional 10,182 shares in the last quarter. Congress Asset Management Co. raised its position in shares of Tango Therapeutics by 9.0% during the 4th quarter. Congress Asset Management Co. now owns 227,989 shares of the company’s stock valued at $704,000 after acquiring an additional 18,919 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new stake in shares of Tango Therapeutics during the 3rd quarter valued at approximately $151,000. 78.99% of the stock is owned by institutional investors and hedge funds.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.